A Wireframe DNA Cube: Antibody Conjugate for Targeted Delivery of Multiple Copies of Monomethyl Auristatin E

被引:26
|
作者
Marcher, Anders [1 ,2 ]
Nijenhuis, Minke A. D. [1 ,2 ]
Gothelf, Kurt V. [1 ,2 ]
机构
[1] Aarhus Univ, Dept Chem, Gustav Wieds Vej 14, DK-8000 Aarhus, Denmark
[2] Aarhus Univ, Interdisciplinary Nanosci Ctr iNANO, Gustav Wieds Vej 14, DK-8000 Aarhus, Denmark
关键词
antibody drug conjugate; atomic force microscopy; controlled DAR; DNA nanotechnology; protein conjugation; DRUG CONJUGATE; TRASTUZUMAB EMTANSINE; CYTOTOXIC DRUG; BREAST-CANCER; RECEPTOR; CELLS; NANOSTRUCTURES; STABILITY; ORIGAMI; LINKER;
D O I
10.1002/anie.202107221
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In recent years, several antibody drug conjugates (ADC) have been accepted by the FDA as therapeutics against cancer. It is well-known that control of drug-to-antibody ratio (DAR) is vital for the success of an ADC, which inspires the advancement of better and simpler methods for tight control of DAR. We present the development of an antibody DNA wireframe cube conjugate for precise control of DAR. The DNA wireframe cube consists of four single strands, which when folded present eight single stranded domains. One domain is bound to a monofunctionalized antibody DNA conjugate, and the seven others are attached to DNA functionalized with the potent tubulin inhibitor MMAE, thereby preparing an ADC with a DAR of precisely seven. The formation of the ADC is investigated by gel electrophoresis and atomic force microscopy. Lastly, the developed MMAE loaded ADC was used for targeted drug delivery in vitro.
引用
收藏
页码:21691 / 21696
页数:6
相关论文
共 50 条
  • [31] Theranostic approach in CD30 positive cancers with a radiolabeled antibody conjugated to the radiosensitizing antitubulin monomethyl auristatin E payload
    Petitot, C.
    Frenay, J.
    Dias, A. M. M.
    Oudot, A.
    Helbling, A.
    Moreau, M.
    Monterrat, M.
    Guillemin, M.
    Ranjit, N.
    Cochet, A.
    Bellaye, P. S.
    Collin, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S335 - S336
  • [32] Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E-based antibody-drug conjugates
    Chang, Hsuan-Ping
    Cheung, Yuen Kiu
    Liu, Shufang
    Shah, Dhaval K.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (07) : 1637 - 1655
  • [33] Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers
    Zhou, Wei
    Fang, Peng
    Yu, Dongan
    Ren, Hongyuan
    You, Meng
    Yin, Long
    Mei, Fei
    Zhu, Huikai
    Wang, Zhenzhen
    Xu, Hui
    Cao, Yuxia
    Sun, Xiaowei
    Xu, Xiaohong
    Bi, Jianjun
    Wang, Jin
    Ma, Lanping
    Wang, Xin
    Chen, Lin
    Zhang, Yongliang
    Cen, Xiaowei
    Zhu, Xi
    Lou, Liguang
    Liu, Datao
    Tan, Xiaoding
    Yang, Jinliang
    Meng, Tao
    Shen, Jingkang
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (08) : 913 - 925
  • [34] Bioanalysis of the Bicycle® toxin conjugate BT5528 and released monomethyl auristatin E via liquid chromatography-tandem mass spectrometry
    Tweed, Joseph A.
    Adams-Dam, Fern
    Allanson, Jane
    Holmes, Kevin
    Senior, Ryan
    Xu, Hongmei
    Li, Mengyao
    Bennett, Gavin
    Jeffrey, Phil
    BIOANALYSIS, 2024, 16 (03) : 155 - 169
  • [35] Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels
    Temming, Kai
    Meyer, Damon L.
    Zabinski, Roger
    Dijkers, Eli C. F.
    Poelstra, Klaas
    Molema, Grietje
    Kok, Robbert J.
    BIOCONJUGATE CHEMISTRY, 2006, 17 (06) : 1385 - 1394
  • [36] Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells
    Damiani, Isabella
    Castiglioni, Silvia
    Sochaj-Gregorczyk, Alicja
    Bonacina, Fabrizia
    Colombo, Irma
    Rusconi, Valentina
    Otlewski, Jacek
    Corsini, Alberto
    Bellosta, Stefano
    BIOLOGY-BASEL, 2021, 10 (08):
  • [37] Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer
    Abdollahpour-Alitappeh, Meghdad
    Lotfinia, Majid
    Bagheri, Nader
    Sepehr, Koushan Sineh
    Habibi-Anbouhi, Mahdi
    Kobarfard, Farzad
    Balalaie, Saeed
    Foroumadi, Alireza
    Abbaszadeh-Goudarzi, Ghasem
    Abbaszadeh-Goudarzi, Kazem
    Abolhassani, Mohsen
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (03) : 2693 - 2704
  • [38] Antibody-DNA nanostructure conjugate enables targeted delivery of gemcitabine to tumor and improves the anti-tumor efficacy
    Li, Chengxun
    Xia, Zuguang
    Li, Shengjie
    Yu, Hongxiu
    JOURNAL OF CONTROLLED RELEASE, 2025, 381
  • [39] Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia
    Pereira, Daniel S.
    Guevara, Claudia
    Verlinsky, Alla
    Virata, Cyrus
    Ssucheng, J. Hsu
    An, Zili
    Zhang, Chungying
    Dinh, Nick
    Avina, Hector
    Do, Lisa
    Karki, Sher
    Abad, Joseph
    Yang, Peng
    Ou, Jimmy
    Morrison, Karen
    Moon, Sing-Ju
    Malik, Faisal
    Jin, Liqing
    Choi, Michael
    Wu, Christina
    Anand, Banmeet
    Cooper, Scott
    Joseph, Ingrid
    Jia, Xiao-Chi
    Morrison, Kendall
    Challita-Eid, Pia
    Donate, Fernando
    Kipps, Thomas
    Dick, John
    Stover, David
    CANCER RESEARCH, 2014, 74 (19)
  • [40] An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer
    Li, Hongwen
    Yu, Chao
    Jiang, Jing
    Huang, Changjiang
    Yao, Xuejing
    Xu, Qiaoyu
    Yu, Fang
    Lou, Liguang
    Fang, Jianmin
    CANCER BIOLOGY & THERAPY, 2016, 17 (04) : 346 - 354